Celmade Receives FDA Warning Letter for Unapproved Injectable Botulinum Toxin Sales into U.S.

Unapproved injectable botulinum toxin products entering U.S. interstate commerce without FDA section 505(a) approval represent precisely the enforcement scenario CDER has escalated through web-based surveillance, and Celmade, a South Korea-based supplier, is now at the center of it. The agency issued Warning Letter MARCS-CMS 735876 on September 14, 2026, citing violations identified during website reviews conducted on August 4 and September 1, 2026.

The letter documents violations of sections 301(a), 301(d), 502(f)(1), 503(b)(1), and 505(a) of the FD&C Act across two commercial domains, www.celmade.co and celmade.net. Products were classified as unapproved new drugs and misbranded drugs, neither carrying the safety and efficacy assurances that accompany FDA-reviewed applications. CDER flagged the absence of approved NDAs under 21 U.S.C. 355 as the primary violation.

For regulatory affairs leads monitoring enforcement trends, the mechanism here is instructive. CDER's review was conducted remotely via website inspection, no physical facility audit was required to trigger formal action. The FEI number assigned (3038674250) confirms the agency has formally registered the establishment in its enforcement tracking system, a step that typically precedes escalated action if the initial letter goes unaddressed.

The sterility assurance concern is explicit in the letter. Injectable drug products bypass the body's mucosal and dermal defenses, creating direct exposure risk from contamination, counterfeit active ingredients, or variable potency, conditions the agency associates with products that have circumvented GMP oversight and pre-market review. CDER noted the particular hazard of botulinum toxin administration outside appropriate medical supervision, citing septicemia and sepsis as life-threatening potential outcomes.

FDA's requested corrective action is unambiguous: cease all U.S.-directed sales of unapproved and misbranded products immediately. The letter also preserves the agency's authority to pursue seizure or injunction without further notice if violations are not adequately resolved, a standard enforcement posture that QA and regulatory teams at any firm distributing injectable biologics or toxins into the U.S. market should read as a signal about CDER's current threshold for escalation.

The Celmade action is one data point in a broader pattern of FDA web-based surveillance targeting offshore suppliers of injectable drug products, and the timeline from site review to warning letter, under six weeks in one instance, reflects the pace at which CDER is now moving on this category.

Source: FDA CDER via FDA.gov Warning Letters database, September 29, 2026.